Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pulmonary Wedge Pressure

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    128 result(s) found for: Pulmonary Wedge Pressure. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2004-003843-28 Sponsor Protocol Number: STH13565 Start Date*: 2005-03-18
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: The acute effects of testosterone administration in patients with pulmonary hypertension
    Medical condition: Pulmonary Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-020153-14 Sponsor Protocol Number: HFpEF Start Date*: 2011-01-12
    Sponsor Name:University Medical Center Groningen
    Full Title: Effects of Sildenafil on pulmonary artery pressure in patients with heart failure with preserved ejection fraction and pulmonary hypertension
    Medical condition: The condition to be investigated is isolated left heart failure , also called heart failure with preserved ejection fraction ( HFpEF) with pulmonary hypertension. HFpEF is a clinical syndrome wit...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022820-61 Sponsor Protocol Number: Tad-10 Start Date*: 2010-10-14
    Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
    Full Title: PHASE CONTRAST MAGNETIC RESONANCE (MR) IMAGING IN MONITORING THE EFFECTS OF TADALAFIL IN PATIENTS WITH OUT-OF-PROPORTION PULMONARY HYPERTENSION AND LEFT VENTRICULAR DYSFUNCTION
    Medical condition: Pulmonary Hypertension ``out-of-proportion`` associated to moderate left ventricular dysfunction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037406 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011006-42 Sponsor Protocol Number: vs.3.23-02-2009 Start Date*: 2009-07-13
    Sponsor Name:Rigshospitalet, Hjertemedicinsk afd. B
    Full Title: Sildenafil and diastolic dysfunction after AMI
    Medical condition: Diastolic dysfunction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052337 Diastolic dysfunction LLT
    9.1 10052337 Diastolic dysfunction PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-017155-10 Sponsor Protocol Number: 10-aifa-2005-01 Start Date*: 2006-11-07
    Sponsor Name:CASA DI CURA PRIVATA S.RAFFAELE - PISANA
    Full Title: Evaluation of tolerability and efficacy of the combination Sildenafil/Bosentan in patients with severe pulmonary hypertension.
    Medical condition: severe pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003975-38 Sponsor Protocol Number: TERPAH-001 Start Date*: 2007-11-22
    Sponsor Name:Ergonex Pharma GmbH
    Full Title: Proof of Concept Study to Investigate the Efficacy, Haemodynamics and Tolerability of Terguride vs. Placebo in Patients with Pulmonary Arterial Hypertension. Double-blind, randomized, prospective P...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) NL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001637-10 Sponsor Protocol Number: 12008 Start Date*: 2008-09-18
    Sponsor Name:HUCH, Division of Cardiology
    Full Title: Acute heart failure in acute coronary syndrome: Double blind comparison of levosimendan and placebo
    Medical condition: Acute coronary syndrome treated with percutaneous coronary intervention (PCI) Patients suffering from acute heart failure after the procedure will be randomised to the study
    Disease: Version SOC Term Classification Code Term Level
    9.1 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000833-35 Sponsor Protocol Number: CRLX030A2201 Start Date*: 2011-10-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, phase II, double blind, randomized, parallel group, placebo-controlled study to evaluate the hemodynamic responses to intravenous RLX030 infusion in subjects with acute heart failure.
    Medical condition: Acute Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10000803 Acute heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-001199-31 Sponsor Protocol Number: 57231 Start Date*: 2017-03-20
    Sponsor Name:
    Full Title: Improving treatment of right ventricular failure in pulmonary hypertension patients.
    Medical condition: End stage right ventricular failure in pulmonary hypertension patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012450-20 Sponsor Protocol Number: AC-051-206 Start Date*: 2009-10-15
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: Multicenter, open-label, non-comparative, proof-of-concept, phase 2a study to evaluate the effect of a single infusion of tezosentan on pulmonary vascular resistance in patients with stable, chroni...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002835-17 Sponsor Protocol Number: 250774 Start Date*: 2016-01-18
    Sponsor Name:Justus Liebig Universität Gießen
    Full Title: Investigation of the influence of PAH-specific medication on right ventricular function in patients with pulmonary arterial hypertension (PAH) under basal conditions
    Medical condition: Pulmonary arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037403 Pulmonary hypertension NOS LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077729 Pulmonary arterial hypertension WHO functional class III LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077740 Pulmonary arterial hypertension WHO functional class II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted)
    Trial results: (No results available)
    EudraCT Number: 2009-010703-80 Sponsor Protocol Number: AC-063A301 Start Date*: 2009-06-11
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Crossover Study to Assess the Effects of a Single Dose of Iloprost Power 15 on Exercise Capacity in Patients with Symptomatic Pulmonary ...
    Medical condition: Indication: Symptomatic Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005462-34 Sponsor Protocol Number: 202006RCT Start Date*: 2021-06-23
    Sponsor Name:Thoraxklinik Heidelberg gGmbH
    Full Title: An open-label, prospective, single centre study of the effects of Riociguat on RIght VEntricular size and function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
    Medical condition: Symptomatic pulmonary arterial hypertension with a mean pulmonary artery pressure >20 mmHg and pulmonary vascular resistance ≥2 Wood Units, pulmonary arterial wedge pressure ≤15 mmHg (Group I / Nic...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-024585-22 Sponsor Protocol Number: WILK3 Start Date*: 2011-03-25
    Sponsor Name:Imperial College Academic Healthsciences Centre
    Full Title: What is the effect of intravenous iron supplementation on cardiopulmonary haemodynamics, exercise capacity and quality of life in patients with IPAH and iron deficiency?
    Medical condition: Idiopathic or familial pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000137-31 Sponsor Protocol Number: 2017-2019 Start Date*: 2017-12-19
    Sponsor Name:VU University Medical Center
    Full Title: Pulmonary Hypertension REversal in Clusters of Patients With Identical Pathobiological Substrates. 6-Mercaptopurine Proof-of-Concept Trial
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037454 Pulmonary vascular disorders HLGT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000670-28 Sponsor Protocol Number: CLTP001A12201 Start Date*: 2022-04-19
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, participant- and investigator-blinded, placebo-controlled study to investigate efficacy, safety and tolerability of LTP001 in participants with pulmonary arterial hypertension
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Ongoing) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002783-12 Sponsor Protocol Number: BAYq6256/16483 Start Date*: 2014-01-07
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAY Q 6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX ne...
    Medical condition: Patients with Pulmonary arterial hypertension, WHO class III, who have been on therpay with Ventavis 10 for at least 4 weeks
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002020-25 Sponsor Protocol Number: 052017 Start Date*: 2018-08-31
    Sponsor Name:Odense University Hospital
    Full Title: ANGIOTENSIN–NEPRILYSIN INHIBITION IN DIASTOLIC DYSFUNCTION AFTER AMI
    Medical condition: Diastolic dysfunction after acute myocardial infarction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004849 10076396 Heart failure with preserved ejection fraction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001675-37 Sponsor Protocol Number: Lis-Safe Start Date*: 2012-07-24
    Sponsor Name:Sinoxa Pharma GmbH
    Full Title: A Prospective, Open-label, Exploratory Study to Investigate the Safety, Efficacy, and Haemodynamics of Lisuride Subcutaneous Infusion as Add-on to Conventional Treatment in Patients with Pulmonary ...
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10036727 Primary pulmonary hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-014246-29 Sponsor Protocol Number: BPS-MR-PAH-203 Start Date*: 2010-02-01
    Sponsor Name:Lung Rx
    Full Title: A 12-week, double-blind, international, multicenter, dose-response study of the safety and efficacy of Beraprost Sodium Modified Release (BPS-MR) in patients with pulmonary arterial hypertension (PAH)
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BE (Prematurely Ended) DE (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 00:57:21 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA